Impilo
VC Fund
Stockholm, Sweden
Impilo is a Nordic investment company focused solely on investments in companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Its starting point is that our portfolio companies must contribute to a positive and sustainable development of the communities and markets in which theyoperate in order to remain successful in the long term. It was founded in 2017 and is based in 2017 and is based in Stockholm, Sweden.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Impilo invests in
Stages Impilo invests in
Countries Impilo invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 3 (75%)
- Pharmaceutical 3 (75%)
- Medical 2 (50%)
- Health Care 2 (50%)
- Medical Device 1 (25%)
Stage
- Funding Round 3 (75%)
- Private Equity 1 (25%)
Country
- Sweden 3 (75%)
- Denmark 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jesper Eliasson
Partner & CFO
|
Partner & CFO | Total investments: 0 | Find email | |
Jens Bager
Industrial Partner
|
Industrial Partner | Total investments: 2 | Find email | |
Magnus Edlund
Partner
|
Partner | Total investments: 1 | Find email | |
Martin Fagerlund
Partner & COO
|
Partner & COO | Total investments: 0 | Find email | |
Sören Mellstig
Co-founder
|
Co-founder | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Immedica
|
Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East.Immedica provides significant know-how and experience from the commercialization of niche/specialty care products across Europe and the Middle East, and the company’smanagement team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access to specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality, and product distribution.Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors. | Private Equity / Apr 23, 2024 | |
Pelago Bioscience
|
Pelago Bioscience offers target engagement studies of drug candidate interactions with target proteins in cells and tissues. | Aug 16, 2023 | |
Scantox
|
Scantox is a contract research organization that specializing in pharmacology and regulatory toxicology services. Their preclinical contract research services enable clients to progress their drug or device development. They offer various contract research services such as safety pharmacology, exploratory, and endotoxin testing. | Jan 26, 2021 | |
Cavidi
|
Cavidi is Sweden’s leading supplier of viral load for HIV monitoring. Cavidi’s products enable efficient management of anti-HIV drugs (ARV therapy) so that people living with HIV can live a normal lifespan. Cavidi’s diagnostics reduce the cost of treatment and the spread of HIV. Cavidi also provides tools and kits for virus research to many of theworld’s leading labs.Cavidi is a Swedish biotech company founded as a spin-off from Uppsala University. Their expertise is based on understanding viruses and using this knowledge to create research tools and clinical diagnostics. Today their focus is on HIV but our methods and expertise can be applied to other viruses.Cavidi’s head office is in Uppsala, Sweden and they have sales offices in South Africa, India and USA. Their customers include hospitals, patient clinics, private laboratories, the pharmaceutical industry and research institutions worldwide. | $11.5M / Feb 27, 2018 |
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Impilo invest in?
Impilo invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Funding Round and Private Equity stage. Most of the 4 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Impilo?
Public channels for Impilo include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Impilo?
The team at Impilo includes Jesper Eliasson (Partner & CFO), Jens Bager (Industrial Partner) and Magnus Edlund (Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
